Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: A retrospective analysis of a single institution

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1837-1840

  Inal, Ali ^a   Kaplan, M Ali ^a   Kucukoner, Mehmet ^a   Urakcl, Zuhat ^a   Karakus, Abdullah ^a   Islkdogan, Abdurrahman ^a  

^a Department of Medical Oncology ^*  (Turkey)

Author keywords

Advanced lung cancer; Cisplatin based therapy; Elderly patients; First line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL; TAXOID;

ADENOCARCINOMA; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 84872677320     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1837     Document Type: Article

References (23)

1. Ansari R, Gonin R, Socinski M (2007). Eldelry subgroup analysis of a radnomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer. Proc Am Soc Clin Oncol, 25, 7665.
2. Ansari RH, Socinski MA, Edelman MJ, et al (2011). A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol, 78,162-71.
3. Belani CP, Fossella F (2005). Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer, 104, 2766-74.
4. Deppermann KM (2011). Influence of age and comorbiditieson the chemotherapeutic management of lung cancer. Lung Cancer, 33, 115-20.
5. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer (1999). The elderly lung cancer vinorelbine Italian study group. J Natl Cancer Inst, 91, 66-72.
6. Havlik RJ, Yancik R, Long S, et al (1994). The national institute on aging and the national cancer institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer, 74, 2101-6.
7. Hensing TA, Peterman AH, Schell MJ, et al (2003). The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer, 98, 779-88.
8. Jatoi A, Hillman S, Stella P, et al (2005). Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the north central cancer treatment group. J Clin Oncol, 23, 9113-9.
9. Kelly K, Giarritta S, Akerley W (2001). Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of southwest oncology trials 9509 and 9308. Proc Am Soc Clin Oncol, 20, 1313.
10. Langer C, Vangel M, Schiller HJ (2003). Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol, 22, 2571.
11. Langer CJ, Manola J, Bernardo P, et al (2002). Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst, 94, 173-81.
12. Maione P, Rossi A, Sacco PC, et al (2010). Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol, 2, 251-60.
13. Nurgalieva Z, Xia R, Liu CC, et al (2010). Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung sancer. Am J Ther, 17, 148-58.
14. Pallis AG, Gridelli C, Van Meerbeeck JP, et al (2010). EORTC elderly task force and lung cancer group and International society for geriatric oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol, 21, 692-706.
15. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
16. Ramalingam S, Perry MC, La Rocca RV, et al (2008). Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer, 113, 542-6.
17. Repetto L, Venturino A, Fratino L, et al (2003). Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer, 39, 870-80.
18. Rocha Lima CM, Herndon JE, Kosty M, Clamon G, Green MR (2002). Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the cancer and leukemia group B. Cancer, 94, 181-7.
19. Schild SE, Stella PJ, Geyer SM, et al (2003). The outcome of combinedmodality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol, 21, 3201-6.
20. Sederholm C, Hillerdal G, Lamberg K, et al (2005). Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish lung cancer study group. J Clin Oncol, 23, 8380-8.
21. Sequist LV, Lynch TJ (2003). Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol, 21, 3186-8.
22. Shepherd FA (1993). Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol, 5, 310-22.
23. Walling J (1994). Chemotherapy for advanced non-small-cell lung cancer. Respir Med, 88, 649-57.